MARKET

ALDX

ALDX

Aldeyra Therapeu
NASDAQ
2.080
-0.130
-5.88%
After Hours: 2.080 0 0.00% 16:11 05/13 EDT
OPEN
2.220
PREV CLOSE
2.210
HIGH
2.260
LOW
2.075
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
7.20
52 WEEK LOW
1.180
MARKET CAP
124.58M
P/E (TTM)
-2.2154
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALDX last week (0505-0509)?
Weekly Report · 1d ago
Aldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities
TipRanks · 5d ago
Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie
TipRanks · 6d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/06 12:08
Aldeyra Therapeutics Achieves Success in Phase 3 Trial
TipRanks · 05/06 11:34
Aldeyra’s reproxalap achieves primary endpoint in Phase 3 dry eye disease trial
TipRanks · 05/05 22:40
ALDEYRA THERAPEUTICS ACHIEVES PRIMARY ENDPOINT IN PHASE 3 DRY EYE DISEASE CHAMBER TRIAL OF REPROXALAP AND PLANS NDA RESUBMISSION
Reuters · 05/05 22:34
Aldeyra Therapeutics To Announce Topline Results From Phase 3 Dry Eye Disease Clinical Trials Of Reproxalap At Conference Call Scheduled On May 6, 2025
Benzinga · 05/05 20:08
More
About ALDX
More
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Recently
Symbol
Price
%Change

Webull offers Aldeyra Therapeutics Inc stock information, including NASDAQ: ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.